Lazar Amends Indaptus Therapeutics Ownership on March 24, 2026

TL;DR

**Lazar just updated his stake in Indaptus Therapeutics, watch for market reaction.**

AI Summary

David E. Lazar, an individual, filed a SCHEDULE 13D/A on March 24, 2026, indicating an amendment to his beneficial ownership in Indaptus Therapeutics, Inc. (CIK: 0001857044). This filing updates previous disclosures about his stake in the pharmaceutical preparations company. For stockholders, this matters because significant changes in ownership by key individuals like Lazar can signal their confidence (or lack thereof) in the company's future, potentially influencing stock price and strategic direction.

Why It Matters

This filing updates the public record on a significant investor's stake, which can influence market perception and potentially the stock's volatility.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership can signal shifts in investor confidence, which carries moderate risk for current and potential shareholders.

Analyst Insight

An investor should monitor subsequent filings from David E. Lazar to understand the nature of the amendment (e.g., increase, decrease, or change in intent) and assess its potential impact on Indaptus Therapeutics, Inc.'s stock price and future strategy.

Key Players & Entities

• Lazar David E. (person) — the individual filing the SCHEDULE 13D/A
• Indaptus Therapeutics, Inc. (company) — the subject company of the filing
• 0001932843 (person) — CIK of Lazar David E.
• 0001857044 (company) — CIK of Indaptus Therapeutics, Inc.
• March 24, 2026 (date) — filing date of the SCHEDULE 13D/A

FAQ

Key Financial Figures

• $0.01 — n-Redeemable Preferred Stock, par value $0.01 per share (the “ Series AA Prefer
• $11,200,000 — on Two Hundred Thousand US Dollars (USD $11,200,000) to be held in an account until release
• $560,000 — nt (5%) of the Purchase Price, equal to $560,000 (the “ Holdback Amount ”) s

Filing Documents

• primary_doc.html (SCHEDULE 13D/A)
• primary_doc.xml (SCHEDULE 13D/A) — 10KB
• indaptus_ex99-2.htm (EX-99.2) — 198KB
• 0001829126-26-002642.txt ( ) — 210KB

From the Filing

EX-99.2 2 indaptus_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CONFIDENTIAL SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “ Agreement ”) is entered into as of this 19 th day of March 2026 (the “ Agreement Date ”), by and among: (i) David Elliot Lazar, an individual, whose address is 44, Tower 100 The Towers, Winston Churchill, San Francisco, Paitilla, Panama City, Panama 07196 (“ Seller ”), (ii) Yun Yao, an Australian citizen and an individual, as the lead investor (“ Lead Purchaser ”), and (iii) each of the undersigned purchasers (each a “ Purchaser ,” and collectively with the Lead Purchaser, the “ Purchasers ”). Seller and Purchasers may be referred to herein as the “ Parties ” and each of them separately as a “ Party .” WHEREAS , Seller, an officer and director of Issuer, is the holder of (i) 300,000 shares of Series AA Convertible Non-Redeemable Preferred Stock, par value $0.01 per share (the “ Series AA Preferred Stock ”), of Indaptus Therapeutics, Inc., a Delaware corporation (the “ Issuer ” and, together with its Subsidiaries, the “ Group ”) (each share of Series AA Preferred Stock shall be convertible into 20 shares of common stock, par value $0.01 per share, of the Issuer (the “ Common Stock ”)) and (ii) 700,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock, par value $0.01 per share (the “ Series AAA Preferred Stock ”), of the Issuer (each share of Series AAA Preferred Stock shall be convertible into 150 shares of Common Stock); WHEREAS, the Purchasers propose to purchase, and the Seller proposes to sell: (i) all of his interest and rights in the 700,000 shares of the Series AAA Convertible Non-Redeemable Preferred Stock (the “ Sold Series AAA ”); and (ii) all of his interest and rights to 196,800 shares of the Series AA Convertible Non-Redeemable Preferred Stock (the “ Sold Series AA ”, together with the Sold Series AAA, the “ Preferred Securities ”), as well as all of the Seller’s rights, titles and interest in the portion of that certain Securities Purchase Agreement dated as of December 22, 2025, between Seller and Issuer, dealing with the Series AAA Preferred Stock and Series AA Preferred Stock, pursuant to which, inter alia, the Seller has acquired the Series AA Preferred Stock and the Series AAA Preferred Stock (the “ Series AA and AAA SPA ”; and together with the Preferred Securities, the “ Investment Assets ”), all pursuant to this Agreement (collectively, the “ Transactions ”); WHEREAS , five percent (5%) of the Purchase Price shall be held in escrow, with such portion of the Purchase Price to be held, applied and released in accordance with the terms of this Agreement and the Escrow Agreement (as defined herein); WHEREAS, pursuant to the Certificate of Designations, Preferences and Rights of the Sold Series AA (the “ AA CoD ”), upon compliance with the provisions therein and further to the Issuer’s stockholders approval of each of (A) an increase in the number of authorized shares of Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Sold Series AA, that is issued and outstanding, and (B) the conversion of the Sold Series AA and any Sold Series AAA that is issued and outstanding into shares of Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the “ Stockholder Approvals ”), and further to the Issuer’s filing of an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ Charter Amendment ”) evidencing such stockholder approval, the holder of the Sold Series AA shall be entitled, at its option, at any time and from time to time, to convert each shares of Sold Series AA into 20 shares of Issuer’s Common Stock, as more fully detailed in the AA CoD (the “ AA Conversion Stock ”); and WHEREAS, pursuant to the Certificate of Designations, Preferences and Rights of the Sold Series AAA (the “ AAA CoD ”), upon compliance with the provisions therein and further to the Stockholder Approvals, and the Issuer’s filing of the Charter Amendment evidencing such Stockholder Approval, the holder of the Sold Series AAA shall be entitled, at its option, at any time and from time to time, to convert each shares of Sold Series AAA into 150 shares of Issuer’s Common Stock, as more fully detailed in the AAA CoD (the “ AAA Conversion Stock ”, together with the AA Conversion Stock and Preferred Securities, the “ Securities ”). The Securities together with the Investment Assets, are referred to as the “ Sold Assets ”; and CONFIDENTIAL NOW, THEREFORE

View Full Filing

View this filing on SEC EDGAR